Rani Therapeutics Holdings, Inc. (RANI): Price and Financial Metrics
RANI Price/Volume Stats
| Current price | $6.56 | 52-week high | $8.75 |
| Prev. close | $6.99 | 52-week low | $1.82 |
| Day low | $6.24 | Volume | 189,600 |
| Day high | $7.23 | Avg. volume | 121,276 |
| 50-day MA | $4.10 | Dividend yield | N/A |
| 200-day MA | $3.35 | Market Cap | 329.03M |
RANI Stock Price Chart Interactive Chart >
Rani Therapeutics Holdings, Inc. (RANI) Company Bio
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was founded in 2012 and is headquartered in San Jose, California.
Latest RANI News From Around the Web
Below are the latest news stories about RANI THERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate RANI as an investment opportunity.
Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin TriagonistPeak Decreases in Body Weights All data are means ± SE - Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study – - Preclinical data support the potential for the RaniPill platform to enable oral delivery of multiple obesity treatments - SAN JOSE, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral de |
What Makes Rani Therapeutics Holdings, Inc. (RANI) a New Buy StockRani Therapeutics Holdings, Inc. (RANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Jean-Luc Butel Buys Handful Of Shares In Rani Therapeutics HoldingsPotential Rani Therapeutics Holdings, Inc. ( NASDAQ:RANI ) shareholders may wish to note that the Independent Director... |
Pleasing Signs As A Number Of Insiders Buy Rani Therapeutics Holdings StockWhen a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase... |
Rani Therapeutics Holdings Inc (RANI) Reports Q3 2023 Financial Results and Corporate DevelopmentsStrategic Focus and Extended Cash Runway Highlighted |
RANI Price Returns
| 1-mo | 116.50% |
| 3-mo | 83.24% |
| 6-mo | 235.55% |
| 1-year | 48.08% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 97.59% |
| 2023 | -43.73% |
| 2022 | -63.91% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...